+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment



Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment



Turk Psikiyatri Dergisi 25(3): 201-211



A significant proportion of patients with schizophrenia receiving clozapine remain with partial response. In this group of patients findings regarding addition of various psychotropics to ongoing clozapine treatment for augmentation are controversial. In this review, literature regarding the efficacy and safety of adjunctive agents in clozapine resistant schizophrenic patients is examined. Augmentation agents added to clozapine in treatment resistant schizophrenic patients consist of antipsychotics, antidepressants, mood stabilizers, other agents (eg. omega 3 fatty acids and glutamatergic agents) and electroconvulsive therapy (ECT) in this review. The number of controlled studies evaluating augmentation of clozapine in schizophrenia patients are highest for risperidone and lamotrigine add on treatments. However, the results of recent meta-analyses studies do not support any benefit of either agent as adjunct to clozapine treatment. Some evidence regarding the success of clozapine augmentation with amisulpride, aripiprazole, mirtazapine, omega 3 fatty acids and ECT have been obtained which needs further clinical investigation. Current findings from relevant clinical studies point that theses studies have limitations of small sample size, variable definitions of clozapine resistance, heterogenity of outcome measures and methodological designs and that sufficient evidence does not yet exist regarding the success of various adjunctive treatments for clozapine resistant patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 051716487

Download citation: RISBibTeXText

PMID: 25219694


Related references

Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophrenia Research 143(1): 207-214, 2013

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series. Turk Psikiyatri Dergisi 27(1): 57-62, 2016

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38(5): 1003-1011, 2012

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 29(1): 28-33, 2006

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. American Journal of Psychiatry 153(12): 1625-1627, 1996

Augmentation strategies in clozapine-resistant schizophrenia. Cns Drugs 19(10): 843-872, 2005

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatrica Scandinavica 110(4): 292-298, 2004

SU114. Switching to Clozapine Treatment in Patients With Schizophrenia: The Clinical Course, Remission, and Augmentation of Treatment After the Switch. Schizophrenia Bulletin 43(Suppl_1): S202-S202, 2017

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biological Psychiatry 42(6): 522-523, 1997

Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology 33(4): 423-435, 2019

Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research 143(2-3): 344-347, 2013

P.3.d.017 Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia patients two case reports and discussion. European Neuropsychopharmacology 24: S530-S531, 2014

Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian and new Zealand Journal of Psychiatry 52(8): 751-767, 2018

Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. Cns Spectrums 19(5): 403-410, 2014